• Loading metrics

Oral Cholera Vaccination Delivery Cost in Low- and Middle-Income Countries: An Analysis Based on Systematic Review

  • Vittal Mogasale ,

    Affiliation International Vaccine Institute, Policy and Economic Research Department, SNU Research Park, Seoul, South Korea

  • Enusa Ramani,

    Affiliation International Vaccine Institute, Policy and Economic Research Department, SNU Research Park, Seoul, South Korea

  • Hyeseung Wee,

    Affiliations International Vaccine Institute, Policy and Economic Research Department, SNU Research Park, Seoul, South Korea, Korea Development Institute, Sejong-si, South Korea

  • Jerome H. Kim

    Affiliation International Vaccine Institute, Policy and Economic Research Department, SNU Research Park, Seoul, South Korea

Oral Cholera Vaccination Delivery Cost in Low- and Middle-Income Countries: An Analysis Based on Systematic Review

  • Vittal Mogasale, 
  • Enusa Ramani, 
  • Hyeseung Wee, 
  • Jerome H. Kim



Use of the oral cholera vaccine (OCV) is a vital short-term strategy to control cholera in endemic areas with poor water and sanitation infrastructure. Identifying, estimating, and categorizing the delivery costs of OCV campaigns are useful in analyzing cost-effectiveness, understanding vaccine affordability, and in planning and decision making by program managers and policy makers.


To review and re-estimate oral cholera vaccination program costs and propose a new standardized categorization that can help in collation, analysis, and comparison of delivery costs across countries.

Data sources

Peer reviewed publications listed in PubMed database, Google Scholar and World Health Organization (WHO) websites and unpublished data from organizations involved in oral cholera vaccination.

Study eligibility criteria

The publications and reports containing oral cholera vaccination delivery costs, conducted in low- and middle-income countries based on World Bank Classification. Limits are humans and publication date before December 31st, 2014.


No participants are involved, only costs are collected.


Oral cholera vaccination and cost estimation.

Study appraisal and synthesis method

A systematic review was conducted using pre-defined inclusion and exclusion criteria. Cost items were categorized into four main cost groups: vaccination program preparation, vaccine administration, adverse events following immunization and vaccine procurement; the first three groups constituting the vaccine delivery costs. The costs were re-estimated in 2014 US dollars (US$) and in international dollar (I$).


Ten studies were identified and included in the analysis. The vaccine delivery costs ranged from US$0.36 to US$ 6.32 (in US$2014) which was equivalent to I$ 0.99 to I$ 16.81 (in I$2014). The vaccine procurement costs ranged from US$ 0.29 to US$ 29.70 (in US$2014), which was equivalent to I$ 0.72 to I$ 78.96 (in I$2014). The delivery costs in routine immunization systems were lowest from US$ 0.36 (in US$2014) equivalent to I$ 0.99 (in I$2014).


The reported cost categories are not standardized at collection point and may lead to misclassification. Costs for some OCV campaigns are not available and analysis does not include direct and indirect costs to vaccine recipients.

Conclusions and implications of key findings

Vaccine delivery cost estimation is needed for budgeting and economic analysis of vaccination programs. The cost categorization methodology presented in this study is helpful in collecting OCV delivery costs in a standardized manner, comparing delivery costs, planning vaccination campaigns and informing decision-making.

Author Summary

We reviewed and re-estimated oral cholera vaccine delivery costs in low and middle income countries standardizing cost categories. The cost categorization proposed here can help in collation, analysis, comparison and economic analysis of OCV delivery costs across countries.


Cholera is transmitted through the fecal-oral route, and humans are the natural host. It is caused by the ingestion of O1 and less commonly O139 serogroups of the Vibrio cholerae bacterium and characterized by severe, potentially life-threatening diarrhea [1]. The disease inflicts a significant health burden on many low-and-middle-income countries (LMICs) in settings where food and water are contaminated with human feces. Infrastructure disruption resulting from natural disasters, civil unrest, and war often precipitates cholera outbreaks, particularly in settings where there is endemic cholera risk. Cholera outbreak risk is further increased when infrastructure disruption is superimposed on the poor sanitation and unsafe drinking water found in parts of Africa, Asia, and South and Central America [2]. While improving water and sanitation infrastructure would greatly enhance the control of cholera in the long-term, the use of preventive vaccines has shown promise in the interim [35].

The struggle to develop a safe and effective cholera vaccine that can prevent and control the disease has a long history. Injectable whole-cell cholera vaccines were developed as early as the 19th century and extensively used in the 20th century in the Indian subcontinent and later abandoned due to their limited efficacy and systemic adverse events [6,7]. Subsequently, a new generation of live-attenuated or killed oral cholera vaccines were developed, licensed, and deployed. A killed whole-cell cholera vaccine with recombinant B subunit of cholera toxin (Dukoral) was licensed in 1991 (two-dose regimen for >2 years of age) [6] and used by travelers visiting cholera-endemic regions. This vaccine received World Health Organization (WHO) prequalification in 2001 and has a price of $5 per dose on the public market. Meanwhile, Vietnam developed and deployed a locally manufactured OCV, ORC-Vax [8]. The vaccine was licensed in 1997 in Vietnam and was modified to mORC-Vax in 2009 after improving the production process. Currently, the price of this vaccine is US$1.25 per dose on Vietnam’s public market. At the same time, international efforts were made to reformulate ORC-Vax into a less expensive modified killed whole-cell OCV, which was first licensed in India in 2009 (Shanchol, two-dose regimen for >1 year of age), and later WHO-prequalified in 2011. Currently, the price of this vaccine is $1.85 per dose on the public market worldwide. A WHO OCV stockpile was then created in 2013 to make the vaccine available and affordable in emergency settings [9,10]. These two WHO-prequalified OCVs, Dukoral and Shanchol have been deployed in mass vaccination campaigns across many endemic regions either pre-emptively or reactively; notably in Haiti, Comoros, Indonesia, Uganda, Mozambique, Tanzania, India, Bangladesh, Guinea, South Sudan, Malawi, Thailand, Ethiopia and Nepal [1121].

A cholera vaccination can be broken down into several small and large activities or actions. Understanding the activities involved in vaccination campaigns and estimating cost of each key activity is vital in planning and deployment of OCVs. When deploying a new vaccine, besides routine recurrent costs, the introduction cost such as initial planning, extra logistics and cold chain, training, social mobilization, sensitization, and other new implementation activities such as management of Adverse Events Following Immunization (AEFI) should be considered [22]. Analysis of cost items helps to identify major cost drivers in mass vaccination programs which are critical elements in planning program implementation. This research intends to assess the costs of the different activities required for OCV delivery in LMICs based on systematic literature search and collection of unpublished data from organizations involved in oral cholera vaccination. We propose to categorize cost items in a standardized method and re-estimate delivery costs. Through this analysis we recommend a standardized cost-collation approach for OCV campaigns that can be used in developing OCV delivery cost-estimation tools and comparing costs across different geographical regions.

Materials and Methods

Search strategy and selection criteria

A systematic literature review was conducted using search terms (vaccination cost) AND (cholera) in Medline database through PubMed restricting search to humans and dated up to December 31, 2014. Detailed search terms are (("vaccination"[MeSH Terms] OR "vaccination"[All Fields]) AND ("economics"[Subheading] OR "economics"[All Fields] OR "cost"[All Fields] OR "costs and cost analysis"[MeSH Terms] OR ("costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields])) AND ("cholera"[MeSH Terms] OR "cholera"[All Fields]) AND (("0001/01/01"[PDAT]: "2014/12/31"[PDAT]) AND "humans"[MeSH Terms]). After initial screening on title and abstract, studies using Dukoral, ORC-Vax and Shanchol conducted in LMICs as per the World Bank’s classification [23] that quantified the costing items in cholera vaccination were included. We excluded costing or cost-effectiveness analyses that used simulated or assumed costs, studies that referred to traveler’s vaccination, and studies that considered vaccination in developed countries. The systematic review followed PRISMA guidelines [24] (S1 Checklist). In addition, to find unpublished literature, we searched the Google Scholar and WHO website for OCV mass campaign-related publications and contacted organizations involved in OCV campaigns, including the International Vaccine Institute (IVI), Medecine sans Frontieres (MSF), and the US Centers for Disease Control and Prevention to obtain available reports.

Categorization of immunization costs

We categorized cost items into four groups with subcategories in each based on the chronological order of implementing OCV campaigns using standardized definitions (Table 1). Vaccination program preparation costs were incurred in field capacity building which includes microplanning, training of personnel, community sensitization, social mobilization and other costs like the storage of vaccines in central warehouses prior to vaccination implementation. Vaccine administration costs included actual vaccine administration costs in the field to individuals as well as transportation of the vaccines from central warehouse to field headquarters and to vaccination field sites. The cost items included are conveyance, per-diem, logistic arrangement, equipment, and location costs for vaccine administration, supervision and monitoring. Finally, all costs related to the AEFI management were included under this category. The last three categories constitute vaccine delivery costs. The vaccine procurement costs included cost of vaccine purchase at preclearance and add-on which comprised costs of freight, insurance, taxes, and customs. This categorization allows comparison of cholera vaccination campaign expenditures across countries that have deployed the vaccines. The financial costs of OCV campaigns were used in our analysis as no opportunity costs were taken into consideration.

Table 1. Cost categorization of oral cholera vaccination campaigns.

Re-estimation of costs

After categorizing costs from each paper we summarized the results and presented overall vaccination program costs as the sum of all four cost categories. As vaccines are often donated to countries, we differentiated overall vaccination program costs and vaccine delivery costs by segregating vaccine procurement costs. We estimated program cost and vaccine delivery cost per person for complete vaccination using three methods: 1) in United States Dollars (US$) as reported in the literature for the campaign year, 2) in 2014 US$ after adjusting for country level inflation and current exchange rate, and 3) in 2014 international dollars (I$) after adjusting for country level inflation and current purchasing power parity. The year 2014 was selected as the base year for cost analysis.

In Method 1, we presented costs as recorded by the investigators for the campaign year (campaign year cost) in US$. Costs in local currency units (LCU) were converted to US$ based on the World Bank exchange rate reference database for that year [25]. In Method 2, we adjusted the base year costs to 2014 US$ cost-equivalent by first converting the costs to LCU for the vaccination year using the US$-LCU exchange rate for that year and inflating it to year 2014 based on the country inflation rate (inflation, consumer prices, annual %) using the World Bank inflation data [25]. The adjusted results were presented in US$ 2014 after converting LCU to US$ based on the 2014 exchange rate. In Method 3, we adjusted the campaign year cost to the 2014 I$ cost-equivalent by first converting the costs to LCU for the vaccination year, and then inflating to the year 2014 as described for Method 2. The adjusted results were presented in I$ after converting LCU to I$ for 2014 [26].

We employed three methods of program cost estimation for two reasons. First, costs from different campaign years and different countries are not comparable and therefore need to be adjusted to the same base year in order to eliminate inflation effects [27]. Second, the exchange rate conversion does not always consider the differences in the cost of living between countries [28]. For example, the vaccination personnel costs (e.g., per diem) vary by country, which cannot be adequately captured in US$. Purchasing power parity expressed in I$, defined as the number of units of a country’s currency required to buy the same amounts of goods and services in the domestic market as US$ would buy in the United States [28], allows comparison across countries.


Systematic review

We identified 83 papers on PubMed search, of which eight were included based on the inclusion-exclusion criteria and two papers were obtained from other sources and personal communications (S1 Flowchart). The program costs for Shanchol delivery were available from four countries (five campaigns) that deployed the vaccine in 2011 and 2014 (Table 2) [1517,21,29]. A publication presented OCV delivery cost summary for a campaign conducted in three internally displaced people (IDP) camps in 2014 in South Sudan without detailed cost categorization [21]. We also obtained more detailed delivery cost for another OCV campaign conducted in South Sudan in 2013 from personal communications [29]. We were aware that in Ethiopia and Malawi, OCV campaigns were conducted in 2015 and delivery costs were estimated [18], but data was unavailable. The program costs for Dukoral were available from four countries that deployed vaccines from 1997 to 2009 [1214,20]. The data for Indonesia was obtained from WHO website [20]. In reference review we found one paper presenting a brief description of a Dukoral campaign in Darfur in 2014 stating direct cost of vaccination was US$336,527 or US$ 7 per full vaccinated person [30]. We had to exclude this study from further analysis because costs could not be categorized. The program costs for ORC-Vax were available from Vietnam that deployed vaccine in a 1998 campaign [31].

Table 2. Oral cholera vaccination costs as reported, adjusted to US$ 2014 and adjusted to 2014 international dollars.

The number of fully vaccinated people per campaign ranged from 23,751 in India to 143,706 in Guinea. The reported price per dose of Shanchol procurement varied from US$ 1.00 to US$ 2.40 while the price of Dukoral ranged from US$ 0 (free) to US$ 5.00.

Categorization of costs

The cost categorization and presentation was inconsistent across the studies conducted as shown in Table 2, limiting their comparability. AEFI management, micro-planning, training, sensitization and social mobilization were often mentioned as activities, but costs were merged with other categories which we could not de-merge. In India, micro-planning was considered as a management activity for existing staff and costs were excluded. In Bangladesh and South Sudan, expenses on office furniture and office supplies were categorized under micro-planning while Indonesia had purchased a computer, which was classified as costs for micro-planning. Costs related to AEFI management were reported only from India, representing 15.73% of the total OCV delivery costs.

Of the four major cost categories, vaccine procurement was the costliest component in all OCV campaigns. Whereas, the vaccine administration was the costliest item under vaccine delivery costs (Table 2). Staff salary and allowance when reported, material and supplies such as vaccination card followed by plastic cups, water and soap, when used, were the cost drivers for vaccine administration. Staff salary and allowances are among the costliest items ranging from 23.6% to 87.8% of delivery costs in Guinea and India, respectively. The material and supplies costed 43.9%, 42.1% and 37.0% of delivery costs in Tanzania, South Sudan (2013) and Uganda respectively.

Re-estimation of costs

Costs re-estimated in US$2014 shows high variability of delivery costs across the sites (Fig 1, Table 2). The variability of delivery costs within the same country was also prominent. Although average delivery cost of OCV campaign in South Sudan IDP camps was $1.72 in US$ 2014 (I$6.57) [21], the costs in three different IDP camps were $1.28(I$4.88), $2.02(I$7.71) and $3.38(I$12.89). When prices were adjusted to I$, the costs of vaccination program increased substantially in all settings enhancing the variability across the sites. For example, the cost per unit of OCV delivery increased from US$ 4.70 to I$ 21.77 in Indonesia.

Fig 1. Vaccine delivery cost presented using three different methods (Method 1 = in USD vaccination year, Method 2 = in USD 2014, Method 3 = in I$ 2014).


When there is a cholera outbreak or an impending outbreak, there are three main intervention options besides management of cases and public awareness: Do nothing, water and sanitation improvement, and cholera vaccination. The cost of inaction against cholera outbreak could be substantial. One study reported that the drop in exports alone results in substantial trade loss accounting up to 1% of the countries’ GDP [32]. Besides exports, the economic impact of a cholera outbreak includes tourism revenue loss, treatment expenditures and loss of income for those who are affected because they are unable to work. Water and sanitation improvement remains the choice of intervention for cholera and other diarrheal disease control, but requires large investments and takes long-term except personal level interventions such as provision of soap for hand wash and chlorine for water purification. The investments needed for upgrading water and sanitation system is difficult to measure and estimates widely vary. One study estimated that the access to regulated in-house piped water supply with quality monitoring and in-house sewerage connection with partial treatment of sewage for all would require a total investment of US$136.5 billion per year [33]. Oral cholera vaccination is the interim intervention that is effective against cholera, at least in short-term. Accordingly, many OCV campaigns have taken place in different parts of the world, but the costs from those studies have been categorized and presented differently. A well-defined and limited set of basic categories may be more helpful to investigators, health authorities, policy makers, vaccination planners, and community stakeholders. The categories described herein allow for a clear, comparative understanding of vaccination campaign costs that can better guide decision-making.

The delivery costs of OCV through mass campaigns differed by country and even within the same country and same settings. The delivery cost of Shanchol in US$ 2014 varied from $1.14 in India to $3.05 in South Sudan per fully immunized person. The difference was higher in I$2014, ranging from I$4.08 in India to I$14.39 in South Sudan. Some of those differences could be because of the difference in provisions and activities during vaccination as discussed below, while other factors could be that the costs are collected and reported differently. However, the costs of OCV delivery in US$ 2014 in three different IDP settings in South Sudan ranged from $1.28 to $3.38 per fully immunized person. This cost difference could be partially attributed to the scale of vaccination, lowest costs of $1.28 was at IDP camp that vaccinated 38,200 people compared to the highest costs of $3.38 was at IDP camp that covered only 7,400 people. Once cost collection, categorization and presentations are standardized, the costs in US$ should help donors and financing bodies to decide the comparative resources required for vaccination in various settings. Whereas the costs in I$ will be helpful in comparing delivery costs across countries when in-country resources are used partially or completely as the case in many preemptive vaccinations in endemic settings.

Vaccine delivery costs were generally higher for Dukoral than Shanchol, with the exception of Uganda. The higher cost of Dukoral delivery could be partially because of its buffer requirement which complicates vaccine administration process requiring more materials and supplies. A higher proportion of delivery costs are constituted by materials and supply as reported in Tanzania (43.9%), Uganda (37.0%) and Mozambique (28.3%) where Dukoral was used. In Tanzania the material and supply costs were high because it included domestic vaccine storage and transport costs. The delivery costs in Uganda was lower because it did not include costs for program preparation (micro-planning, training, social mobilization & sensitization and other preparation costs) and cold chain costs as the campaign used existing cold chain system for vaccine storage at operational headquarters (Entebbe) and did not use cold chain at field level (Adjumani). Also, vaccination coverage and acceptability survey, and AEFI data collections were not accounted for in the costs. In Uganda, Mozambique and Indonesia the vaccine was air-delivered to the site of vaccination due to difficulty in transport or security reasons or due to the fear of breaking the cold chain, which added substantially to the costs.

The costs of Shanchol delivery were highest in 2013 campaign in South Sudan compared to the other three countries that deployed the vaccine. In South Sudan 2013 campaign, items such as soap, cup and water was provided to Shanchol recipients, resulting in increased proportion of material and supply costs (42.1%). This was higher than other sites such as Bangladesh (13.6%) where these provisions were a part of a research activity and in Guinea (14.3%) where such provisions were part of outbreak preventive measures. Costs for Shanchol delivery were next highest in Guinea because of the transport costs where vaccination teams were mobile on car or boat. The proportion of staff salary and allowances as a part of vaccine administration cost was high in India (87.8%) and Bangladesh (62.7%) compared to Guinea (23.6%) and South Sudan (25.3%). The proportion was high in India because it included staff training costs and in Bangladesh it included costs for pre-vaccination census and intensive house to house mop-up vaccination.

The overall costs for administering ORC-Vax was relatively cheaper in Vietnam compared to other OCVs partly due to the fact that it was integrated into their routine immunization system [31]. This suggests that the routine administration of OCV through existing immunization systems may reduce the vaccine delivery costs. However, the staff costs as a proportion of vaccine administration costs were relatively high (75.9%).

Vaccine procurement accounts for the highest proportion of the total vaccination program costs, the majority of which is due to the cost of the vaccine itself. Even if a country receives donated OCVs, international transportation of the donated vaccines to its borders as well as the clearance of the vaccines at the point of entry accounts for a sizable proportion of the costs. Besides scaling up vaccine supply through the entry of multiple competitive manufacturers [34], a single dose vaccine strategy, if deployed, particularly in outbreak settings is likely to lower vaccine costs [35]. The vaccine administration cost was the next highest because it involves intensive efforts to reach each individual to be vaccinated that needs lot of human resources, cold chain and materials such as vaccination card, soap, water and cups. As Shanchol does not need buffer, administering vaccine without provision of water and keeping OCV outside the cold chain could reduce some of these costs [36].

There are several limitations in our analysis. First, the studies analyzed included only direct costs. The indirect costs—such as loss of income and transportation costs for those who spend time to visit a vaccination post [37] are not accounted for. Adding these vaccine recipient costs would be valuable for a better understanding of the total costs of vaccination and help in developing plans to reduce vaccine recipient’s costs which may improve vaccine acceptance [38]. Two of the Shanchol costing studies later published OCV delivery costs under societal perspective [37,39]. Second, several of the studies included in our analysis organized the costs using their own methods and costing categories, which made it difficult to reorganize the costs for the purposes of our analysis [1214,20]. This insufficient and unclear information may have resulted in some misclassification of cost categories. Third, we only could include financial costs, not economic costs as most studies presented financial costs. Inclusion of economic costs in future studies is important to understand all the costs-involved in conducting OCV campaigns and also to conduct cost-effectiveness analysis. Fourth, the presentation of costs in selected papers did not allow us to differentiate between fixed and variable costs. The fixed costs will not be affected by a larger OCV introduction while, the variable costs per unit will be further reduced by scaling up the program. It is important to identify and list fixed and variable costs in future costing studies. Fifth, the scope of this work was confined to vaccine delivery costs and it does not include value for money measures such as cost-effectiveness analysis. The reviews on health economic evaluations around OCV delivery will be useful in informed decision making. Finally, availability of unpublished data from two sites (Malawi and Ethiopia) would have improved the cost estimation.


Understanding the costs of cholera vaccination campaigns is of paramount importance in the economic evaluation as well as in planning future vaccination programs. Currently, there is limited OCV delivery cost data, collected inconsistently and reported capriciously limiting the comparability of costs across settings. Categorizing the costs into easily differentiable categories is useful to the planning process and comparison between campaigns. We recommend that future OCV costing studies include both financial and economic costs and use the cost categories defined in this study for clearer collation, analysis, and comparison of campaign costs.


We thank Iza Ciglenecki of MSF for sharing the report on Maban Country for OCV mass vaccination.

Author Contributions

  1. Conceptualization: VM.
  2. Data curation: ER VM.
  3. Formal analysis: ER HW VM.
  4. Funding acquisition: VM.
  5. Investigation: ER HW VM.
  6. Methodology: VM ER HW.
  7. Project administration: VM JK.
  8. Resources: VM JK.
  9. Software: ER.
  10. Supervision: VM JK.
  11. Validation: ER VM HW JK.
  12. Visualization: ER VM.
  13. Writing – original draft: ER VM.
  14. Writing – review & editing: VM ER HW JK.


  1. 1. Publication WHO (2010) Cholera vaccines: WHO position paper-Recommendations. Vaccine 28: 4687–4688. pmid:20483196
  2. 2. Zuckerman JN, Rombo L, Fisch A (2007) The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 7: 521–530. pmid:17584531
  3. 3. Wierzba TF, Kar SK, Mogasale VV, Kerketta AS, You YA, et al. (2015) Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. Vaccine 33: 2463–2469. pmid:25850019
  4. 4. Severe K, Rouzier V, Anglade SB, Bertil C, Joseph P, et al. (2016) Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up. Am J Trop Med Hyg 94: 1136–1142. pmid:26928838
  5. 5. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, et al. (2014) Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370: 2111–2120. pmid:24869721
  6. 6. Clemens J, Shin S, Sur D, Nair GB, Holmgren J (2011) New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol 8: 701–710. pmid:22064524
  7. 7. Hill DR, Ford L, Lalloo DG (2006) Oral cholera vaccines: use in clinical practice. Lancet Infect Dis 6: 361–373. pmid:16728322
  8. 8. Anh DD, Lopez AL, Tran HT, Cuong NV, Thiem VD, et al. (2014) Oral cholera vaccine development and use in Vietnam. PLoS Med 11: e1001712. pmid:25180511
  9. 9. Yen C, Hyde TB, Costa AJ, Fernandez K, Tam JS, et al. (2015) The development of global vaccine stockpiles. Lancet Infect Dis 15: 340–347. pmid:25661473
  10. 10. Nelson CB, Mogasale V, Bari TI, Clemens JD (2014) Considerations around the introduction of a cholera vaccine in Bangladesh. Vaccine 32: 7033–7036. pmid:24856784
  11. 11. Martin S, Lopez AL, Bellos A, Deen J, Ali M, et al. (2014) Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ 92: 881–893. pmid:25552772
  12. 12. Legros D, Paquet C, Perea W, Marty I, Mugisha NK, et al. (1999) Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. Bull World Health Organ 77: 837–842. pmid:10593032
  13. 13. Cavailler P, Lucas M, Perroud V, McChesney M, Ampuero S, et al. (2006) Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine 24: 4890–4895. pmid:16298025
  14. 14. Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, et al. (2012) Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis 6: e1844. pmid:23056660
  15. 15. Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, et al. (2014) Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis 8: e2629. pmid:24516675
  16. 16. Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, et al. (2013) Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 31: 6058–6064. pmid:24161413
  17. 17. Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, et al. (2013) Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med 10: e1001512. pmid:24058301
  18. 18. Chiwanda M (2015) 160 000 people targeted with oral cholera vaccine in Nsanje. International Vaccine Institute.News releases and statements no. 141.
  19. 19. Phares CR, Date K, Travers P, Deglise C, Wongjindanon N, et al. (2016) Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand. Vaccine 34: 128–133. pmid:26549363
  20. 20. (2006) Use of the two-dose oral cholera vaccine in the context of a major natural disaster: report of a mass vaccination campaign in Aceh Province, Indonesia, 2005. Geneva: World Health Organization.
  21. 21. (2014) Oral cholera vaccine campaign among internally displaced persons in South Sudan. Wkly Epidemiol Rec 89: 214–220. pmid:24864347
  22. 22. Levin A, Wang SA, Levin C, Tsu V, Hutubessy R (2014) Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLoS One 9: e101114. pmid:24968002
  23. 23. (2015) The World Bank. New Country Classifications.
  24. 24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 6: e1000097. pmid:19621072
  25. 25. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, et al. (2013) 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 13: 1050–1056. pmid:24140390
  26. 26. You YA, Ali M, Kanungo S, Sah B, Manna B, et al. (2013) Risk map of cholera infection for vaccine deployment: the eastern Kolkata case. PLoS One 8: e71173. pmid:23936491
  27. 27. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S (2011) Applied methods of cost-effectiveness analysis in health care. Oxford: Oxford University Press.
  28. 28. Ali M, Sur D, You YA, Kanungo S, Sah B, et al. (2013) Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis 56: 1123–1131. pmid:23362293
  29. 29. MSF (2012) Mass Oral Cholera Vaccination Campaign (OCV) in Maban County in the refugee camps and host population in the direct surroundings of the camps. Medecins sans Frontieres Holland.
  30. 30. Chaignat CL, Monti V (2007) Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO. J Health Popul Nutr 25: 244–261. pmid:17985828
  31. 31. Vu DT, Hossain MM, Nguyen DS, Nguyen TH, Rao MR, et al. (2003) Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 21: 304–308. pmid:15043004
  32. 32. Kimball AM, Wong KY, Taneda K (2005) An evidence base for International Health Regulations: quantitative measurement of the impacts of epidemic disease on international trade. Rev Sci Tech 24: 825–832. pmid:16642753
  33. 33. WHO (2004) Costs and benefits of water and sanitation improvements at the global level (Evaluation of the).
  34. 34. Desai SN, Pezzoli L, Martin S, Costa A, Rodriguez C, et al. (2016) A second affordable oral cholera vaccine: implications for the global vaccine stockpile. Lancet Glob Health 4: e223–224. pmid:27013303
  35. 35. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, et al. (2015) The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Med 12: e1001867. pmid:26305226
  36. 36. Saha A, Khan A, Salma U, Jahan N, Bhuiyan TR, et al. (2016) The oral cholera vaccine Shanchol when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine 34: 1551–1558. pmid:26896684
  37. 37. Mogasale V, Kar SK, Kim JH, Mogasale VV, Kerketta AS, et al. (2015) An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India. PLoS Negl Trop Dis 9: e0004072. pmid:26352143
  38. 38. Jeuland M, Lucas M, Clemens J, Whittington D (2010) Estimating the private benefits of vaccination against cholera in Beira, Mozambique: A travel cost approach. J Dev Econ 91: 310–322.
  39. 39. Sarker AR, Islam Z, Khan IA, Saha A, Chowdhury F, et al. (2015) Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh. Vaccine 33: 4916–4921. pmid:26232545